- Acquired by Olympus Corporation for $270M, May 2026
- Raised $28M Series D led by MVM Life Science Partners, Sep 2023
- Raised $25M Series D, Sep 2020
About
BioProtect is an Israeli medical device company that develops innovative biodegradable implant technologies to improve prostate cancer care. Its flagship product, the BioProtect Balloon Spacer system, is designed to provide consistent spacing between the prostate and other critical structures, thereby protecting healthy tissues during radiation therapies. The implant naturally biodegrades after treatment. The company received FDA approval at the end of 2023 and commercially launched its product in 2023, with sales in the United States and Europe. Since its commercial introduction, the Balloon Spacer has been used in over 11,000 procedures worldwide. BioProtect generated $8 million in revenue in 2024, rising to $14.5 million in 2025. BioProtect was acquired by Olympus Corporation for $270 million in May 2026.
Funding history · 8 rounds · $80.0M total
Q&A
- What is BioProtect's primary product?
- BioProtect develops the BioProtect Balloon Spacer system, a biodegradable balloon implant designed to protect healthy tissues during prostate cancer radiation therapy by providing consistent spacing between the prostate and other critical structures.
- When did BioProtect receive FDA approval for its product?
- BioProtect received FDA approval for its BioProtect Balloon Spacer system at the end of 2023.
- When was BioProtect acquired and by whom?
- BioProtect was acquired by Olympus Corporation for $270 million in May 2026.
- What was BioProtect's revenue in 2024 and 2025?
- BioProtect generated $8 million in revenue in 2024, which rose to $14.5 million in 2025.
- How many procedures has the BioProtect Balloon Spacer been used in since its commercial launch?
- Since its commercial introduction, the BioProtect Balloon Spacer has been used in over 11,000 procedures worldwide.
- What was BioProtect's most recent funding round before its acquisition?
- BioProtect completed a Series D funding round in September 2023, raising $28 million. MVM Life Science Partners was a lead investor in this round.
- How many employees does BioProtect have?
- BioProtect has 51–200 employees.
- Where is BioProtect's headquarters located?
- BioProtect's headquarters is located in Netanya, Israel.
Team · 7
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bioprotect.com |
|---|---|
| linkedin.com/company/439364 |
Identifiers & details
| Legal name | BioProtect Ltd. |
|---|---|
| Founded | 2004-9 |
| Employees (exact) | 130 |
Acquisitions & public offerings
Acquired by Olympus Corporation 2026-05 $270.0M
Radar intelligence
Patents
| EPO | 19 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
GitHub
| Top repos | BioProtect-Marine-Planner-UI, BioProtect-Marine-Planner-Server, Engage |
|---|
Web history (Wayback)
| Domain | bioprotect.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|